michellehull

Global Head, Patient Advocacy & Early Access, Oncology. Johnson and Johnson Innovative Medicine.

[Mark Wildgust (he/him) @MAWildgust]

Developing new medicines takes great science + great clinical collaboration. @DrFelixGuerrero displayed that partnership today in his outstanding presentation at #AUA25! Innovation is a team sport + @JNJInnovMed we innovate with and for physicians for their patients. #MyCompany

[Mark Wildgust (he/him) @MAWildgust]

I am looking forward to the sun rising and coming up on our @JNJInnovMed new #bladdercancer data here at #AUA25. New options are needed for #NMIBC. Two back to back plenaries here and back to back plenaries from AUA 24 and 25! #MyCompany

[J&J Innovative Medicine @JNJInnovMed]

#BREAKING: Topline results for the key secondary endpoint of overall survival from the Phase 3 MARIPOSA study highlight treatment progress for patients with EGFR-mutated #NSCLC: https://t.co/l3tpGs7VJT #JNJOncology

[J&J Innovative Medicine @JNJInnovMed]

#NEWS: The U.S. FDA has approved our chemotherapy-free combination regimen for the first-line treatment of patients living with non-small cell lung cancer (NSCLC) with specific EGFR mutations. Read about this new and important treatment option for #NSCLC: https://t.co/1ZNvSlHJlC

[J&J Innovative Medicine @JNJInnovMed]

#NEWS: We're pleased to announce the U.S. FDA has granted priority review of our application for a subcutaneous treatment for patients with EGFR-mutated #NSCLC. Learn more about the submission: https://t.co/tjb3kNYZJY

[michellehull @michellehull]

@salesforce #df12 thanks for the opportunity to meet Mr. Robbins....and Saasy